Evista (chemical name: raloxifene) is a selective estrogen receptor modulator (SERM) approved by the FDA to treat and prevent osteoporosis in postmenopausal women.
Evista also is approved to reduce the risk of hormone-receptor-positive breast cancer in postmenopausal women diagnosed with osteoporosis, as well as postmenopausal women who don’t have osteoporosis but who are at higher-than-average risk for breast cancer.
Evista is a pill taken by mouth once a day.
Learn more about Evista.
Can we help guide you?
Create a profile for better recommendations
Breast self-exam, or regularly examining your breasts on your own, can be an important way to...
- Triple-Negative Breast Cancer (Redirect)
What Is Breast Implant Illness?
Breast implant illness (BII) is a term that some women and doctors use to refer to a wide range...